|
1
|
Cordera F and Jordan VC: Steroid receptors
and their role in the biology and control of breast cancer growth.
Semin Oncol. 33:631–641. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang B, Warner M and Gustafsson JÅ:
Estrogen receptors in breast carcinogenesis and endocrine therapy.
Mol Cell Endocrinol. 418:240–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnston SR: New strategies in estrogen
receptor-positive breast cancer. Clin Cancer Res. 16:1979–1987.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jager NG, Linn SC, Schellens JH and
Beijnen JH: Tailored tamoxifen treatment for breast cancer
patients: A perspective. Clin Breast Cancer. 15:241–244. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prossnitz ER and Arterburn JB:
International union of basic and clinical pharmacology. XCVII. G
protein-coupled estrogen receptor and its pharmacologic modulators.
Pharmacol Rev. 67:505–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filardo EJ, Graeber CT, Quinn JA, Resnick
MB, Giri D, DeLellis RA, Steinhoff MM and Sabo E: Distribution of
GPR30, a seven membrane-spanning estrogen receptor, in primary
breast cancer and its association with clinicopathologic
determinants of tumor progression. Clin Cancer Res. 12:6359–6366.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Q, Li JG, Zheng XY, Jin F and Dong HT:
Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast
carcinomas. Chin Med J (Engl). 122:2763–2769. 2009.PubMed/NCBI
|
|
8
|
Marjon NA, Hu C, Hathaway HJ and Prossnitz
ER: G protein-coupled estrogen receptor regulates mammary
tumorigenesis and metastasis. Mol Cancer Res. 12:1644–1654. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Revankar CM, Cimino DF, Sklar LA,
Arterburn JB and Prossnitz ER: A transmembrane intracellular
estrogen receptor mediates rapid cell signaling. Science.
307:1625–1630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yilmaz M, Christofori G and Lehembre F:
Distinct mechanisms of tumor invasion and metastasis. Trends Mol
Med. 13:535–541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS,
Di GH, Liu G, Li FM, Ou ZL, et al: Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in patients with lymph
node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu HD, Yan Y, Cao XF, Tan PZ, Wen HX, Lv
CM, Li XM and Liu GY: The expression of a novel estrogen receptor,
GPR30, in epithelial ovarian carcinoma and its correlation with
MMP-9. Sheng Li Xue Bao. 62:524–528. 2010.(In Chinese). PubMed/NCBI
|
|
14
|
Long L, Cao Y and Tang LD: Transmembrane
estrogen receptor GPR30 is more frequently expressed in malignant
than benign ovarian endometriotic cysts and correlates with MMP-9
expression. Int J Gynecol Cancer. 22:539–545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan Y, Liu H, Wen H, Jiang X, Cao X, Zhang
G and Liu G: The novel estrogen receptor GPER regulates the
migration and invasion of ovarian cancer cells. Mol Cell Biochem.
378:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rossi RE, Pericleous M, Mandair D, Whyand
T and Caplin ME: The role of dietary factors in prevention and
progression of breast cancer. Anticancer Res. 34:6861–6875.
2014.PubMed/NCBI
|
|
17
|
Hui C, Qi X, Qianyong Z, Xiaoli P, Jundong
Z and Mantian M: Flavonoids, flavonoid subclasses and breast cancer
risk: A meta-analysis of epidemiologic studies. PLoS One.
8:e543182013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho YA, Kim J, Park KS, Lim SY, Shin A,
Sung MK and Ro J: Effect of dietary soy intake on breast cancer
risk according to menopause and hormone receptor status. Eur J Clin
Nutr. 64:924–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takemura H, Sakakibara H, Yamazaki S and
Shimoi K: Breast cancer and flavonoids - a role in prevention. Curr
Pharm Des. 19:6125–6132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moon YJ, Wang X and Morris ME: Dietary
flavonoids: Effects on xenobiotic and carcinogen metabolism.
Toxicol In Vitro. 20:187–210. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Po LS, Chen ZY, Tsang DS and Leung LK:
Baicalein and genistein display differential actions on estrogen
receptor (ER) transactivation and apoptosis in MCF-7 cells. Cancer
Lett. 187:33–40. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang HT, Chou CT, Kuo DH, Shieh P, Jan CR
and Liang WZ: The mechanism of Ca(2+) movement in the involvement
of baicalein-induced cytotoxicity in ZR-75-1 human breast cancer
cells. J Nat Prod. 78:1624–1634. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shang D, Li Z, Zhu Z, Chen H, Zhao L, Wang
X and Chen Y: Baicalein suppresses 17-β-estradiol-induced
migration, adhesion and invasion of breast cancer cells via the G
protein-coupled receptor 30 signaling pathway. Oncol Rep.
33:2077–2085. 2015.PubMed/NCBI
|
|
24
|
Wang L, Ling Y, Chen Y, Li CL, Feng F, You
QD, Lu N and Guo QL: Flavonoid baicalein suppresses adhesion,
migration and invasion of MDA-MB-231 human breast cancer cells.
Cancer Lett. 297:42–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen P, Lu N, Ling Y, Chen Y, Hui H, Lu Z,
Song X, Li Z, You Q and Guo Q: Inhibitory effects of wogonin on the
invasion of human breast carcinoma cells by downregulating the
expression and activity of matrix metalloproteinase-9. Toxicology.
282:122–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pello OM, De Pizzol M, Mirolo M, Soucek L,
Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, et
al: Role of c-MYC in alternative activation of human macrophages
and tumor-associated macrophage biology. Blood. 119:411–421. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferreira E and Cronjé MJ: Selection of
suitable reference genes for quantitative real-time PCR in
apoptosis-induced MCF-7 breast cancer cells. Mol Biotechnol.
50:121–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dowsett M, Cuzick J, Ingle J, Coates A,
Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, et al:
Meta-analysis of breast cancer outcomes in adjuvant trials of
aromatase inhibitors versus tamoxifen. J Clin Oncol. 28:509–518.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maggiolini M and Picard D: The unfolding
stories of GPR30, a new membrane-bound estrogen receptor. J
Endocrinol. 204:105–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang D, Hu L, Zhang G, Zhang L and Chen C:
G protein-coupled receptor 30 in tumor development. Endocrine.
38:29–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Catalano S, Giordano C, Panza S, Chemi F,
Bonofiglio D, Lanzino M, Rizza P, Romeo F, Fuqua SA, Maggiolini M,
et al: Tamoxifen through GPER upregulates aromatase expression: A
novel mechanism sustaining tamoxifen-resistant breast cancer cell
growth. Breast Cancer Res Treat. 146:273–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ruan SQ, Wang ZH, Wang SW, Fu ZX, Xu KL,
Li DB and Zhang SZ: Heregulin-β1-induced GPR30 upregulation
promotes the migration and invasion potential of SkBr3 breast
cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochem Biophys Res
Commun. 420:385–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du GQ, Zhou L, Chen XY, Wan XP and He YY:
The G protein-coupled receptor GPR30 mediates the proliferative and
invasive effects induced by hydroxytamoxifen in endometrial cancer
cells. Biochem Biophys Res Commun. 420:343–349. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thompson EW, Reich R, Shima TB, Albini A,
Graf J, Martin GR, Dickson RB and Lippman ME: Differential
regulation of growth and invasiveness of MCF-7 breast cancer cells
by antiestrogens. Cancer Res. 48:6764–6768. 1988.PubMed/NCBI
|
|
38
|
Nilsson UW, Garvin S and Dabrosin C: MMP-2
and MMP-9 activity is regulated by estradiol and tamoxifen in
cultured human breast cancer cells. Breast Cancer Res Treat.
102:253–261. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fedele P, Calvani N, Marino A, Orlando L,
Schiavone P, Quaranta A and Cinieri S: Targeted agents to reverse
resistance to endocrine therapy in metastatic breast cancer: Where
are we now and where are we going? Crit Rev Oncol Hematol.
84:243–251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ignatov A, Ignatov T, Weissenborn C,
Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD and
Kalinski T: G-protein-coupled estrogen receptor GPR30 and tamoxifen
resistance in breast cancer. Breast Cancer Res Treat. 128:457–466.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G and
Yang G: GPR30 as an initiator of tamoxifen resistance in
hormone-dependent breast cancer. Breast Cancer Res. 15:R1142013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin CW, Yang LY, Shen SC and Chen YC:
IGF-I plus E2 induces proliferation via activation of ROS-dependent
ERKs and JNKs in human breast carcinoma cells. J Cell Physiol.
212:666–674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Branham WS, Dial SL, Moland CL, Hass BS,
Blair RM, Fang H, Shi L, Tong W, Perkins RG and Sheehan DM:
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen
receptor. J Nutr. 132:658–664. 2002.PubMed/NCBI
|
|
44
|
Shenouda NS, Zhou C, Browning JD, Ansell
PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common
herbs regulate prostate cancer cell growth in vitro. Nutr Cancer.
49:200–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
